Apo-Lithium Carbonate · DIN 02242837 · 150mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Lithium Carbonate · DIN 02242837
Manufacturer: Apotex Inc.; listing date 2001-10-11
Health Canada: Marketed since 2001-02-12 · brand APO-LITHIUM CARBONATE · ATC N05AN01 LITHIUM · form Capsule · route Oral · ingredients LITHIUM CARBONATE 150 MG · company Apotex inc · schedule Prescription
Apo-Lithium Carbonate: Formulary list price $0.0667/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0667 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66667 · Verify on the e-Formulary ↗ (DIN 02242837)
Source record
DIN 02242837: Apo-Lithium Carbonate
Raw flags: sec3=Y
Item: 281612008; group id 512; item number 1352; lccId None; manufacturer id APX
Source form: Cap; strength: 150mg
Recorded listing: General benefit
Source prices (unrounded): $0.0667; ministry $0.0667
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242837
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66667Interchangeable products
Carbolith · DIN 00461733 · $0.0667
PMS-Lithium Carbonate · DIN 02216132 · $0.0667
Shortage status: resolved shortage (ended 2024-05-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242837
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Carbolith · DIN 00461733 · 150mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Carbolith · DIN 00461733
Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01
Health Canada: Marketed since 2019-06-03 · brand CARBOLITH · ATC N05AN01 LITHIUM · form Capsule · route Oral · ingredients LITHIUM CARBONATE 150 MG · company Bausch health, canada inc. · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3414 · Verify on the e-Formulary ↗ (DIN 00461733)
Source record
DIN 00461733: Carbolith
Raw flags: sec3=Y
Item: 281612008; group id 512; item number 1352; lccId None; manufacturer id VAL
Source form: Cap; strength: 150mg
Recorded listing: General benefit
Source prices (unrounded): $0.1591; ministry $0.0667
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00461733
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3414Interchangeable products
Apo-Lithium Carbonate · DIN 02242837 · $0.0667
PMS-Lithium Carbonate · DIN 02216132 · $0.0667
Shortage status: discontinued (2025-01-20, reported by BAUSCH HEALTH, CANADA INC.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00461733
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Lithane · DIN 02013231 · 150mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lithane · DIN 02013231
Manufacturer: Searchlight Pharma Inc.; listing date 1996-10-01
Health Canada: Marketed since 2022-09-23 · brand LITHANE · ATC N05AN01 LITHIUM · form Capsule · route Oral · ingredients LITHIUM CARBONATE 150 MG · company Searchlight pharma inc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13626 · Verify on the e-Formulary ↗ (DIN 02013231)
Source record
DIN 02013231: Lithane
Raw flags: sec3=Y
Item: 281612014; group id 512; item number 1353; lccId None; manufacturer id SLP
Source form: Cap; strength: 150mg
Recorded listing: General benefit
Source prices (unrounded): $0.1892; ministry $0.0667
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02013231
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13626Interchangeable products
Apo-Lithium Carbonate · DIN 09857532 · $0.0667
Shortage status: active shortage (reported 2024-05-13, last updated 2026-02-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02013231
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Lithium Carbonate · DIN 02216132 · 150mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Lithium Carbonate · DIN 02216132
Manufacturer: Pharmascience Inc.; listing date 1997-04-10
Health Canada: Marketed since 1996-12-31 · brand PMS-LITHIUM CARBONATE - CAP 150MG · ATC N05AN01 LITHIUM · form Capsule · route Oral · ingredients LITHIUM CARBONATE 150 MG · company Pharmascience inc · schedule Prescription
PMS-Lithium Carbonate: Formulary list price $0.0667/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0667 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19894 · Verify on the e-Formulary ↗ (DIN 02216132)
Source record
DIN 02216132: PMS-Lithium Carbonate
Raw flags: sec3=Y
Item: 281612008; group id 512; item number 1352; lccId None; manufacturer id PMS
Source form: Cap; strength: 150mg
Recorded listing: General benefit
Source prices (unrounded): $0.0667; ministry $0.0667
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02216132
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19894Interchangeable products
Apo-Lithium Carbonate · DIN 02242837 · $0.0667
Carbolith · DIN 00461733 · $0.0667
Shortage status: resolved shortage (ended 2024-04-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02216132
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Lithane · DIN 00406775 · 300mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lithane · DIN 00406775
Manufacturer: Searchlight Pharma Inc.; listing date 1996-10-01
Health Canada: Marketed since 2022-09-22 · brand LITHANE · ATC N05AN01 LITHIUM · form Capsule · route Oral · ingredients LITHIUM CARBONATE 300 MG · company Searchlight pharma inc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3192 · Verify on the e-Formulary ↗ (DIN 00406775)
Source record
DIN 00406775: Lithane
Raw flags: sec3=Y
Item: 281612016; group id 512; item number 1355; lccId None; manufacturer id SLP
Source form: Cap; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $0.1892; ministry $0.0657
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00406775
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3192Interchangeable products
Apo-Lithium Carbonate · DIN 09857540 · $0.0657
Shortage status: active shortage (reported 2024-07-02, last updated 2026-02-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00406775
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Lithmax · DIN 02266695 · 300mg · extended release tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lithmax · DIN 02266695
Manufacturer: A A Pharma Inc.; listing date 2008-06-27
Health Canada: Marketed since 2011-01-14 · brand LITHMAX · ATC N05AN01 LITHIUM · form Tablet (extended-release) · route Oral · ingredients LITHIUM CARBONATE 300 MG · company Aa pharma inc · schedule Prescription
Lithmax: Formulary list price $0.2880/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2880 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75210 · Verify on the e-Formulary ↗ (DIN 02266695)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02266695).
DIN 02266695: Lithmax
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 281612027; group id 512; item number 1356; lccId None; manufacturer id AAP
Source form: ER Tab; strength: 300mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2880; ministry $0.2880
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02266695
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75210Interchangeable products
Duralith · DIN 00590665 · not recorded
Shortage status: resolved shortage (ended 2024-07-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02266695
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Lithium Carbonate · DIN 02242838 · 300mg · capsule
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Lithium Carbonate · DIN 02242838
Manufacturer: Apotex Inc.; listing date 2001-10-11
Health Canada: Dormant since 2026-02-05 · brand APO-LITHIUM CARBONATE · ATC N05AN01 LITHIUM · form Capsule · route Oral · ingredients LITHIUM CARBONATE 300 MG · company Apotex inc · schedule Prescription
Apo-Lithium Carbonate: Formulary list price $0.0657/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0657 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66668 · Verify on the e-Formulary ↗ (DIN 02242838)
Source record
DIN 02242838: Apo-Lithium Carbonate
Raw flags: sec3=Y
Item: 281612002; group id 512; item number 1354; lccId None; manufacturer id APX
Source form: Cap; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $0.0657; ministry $0.0657
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242838
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66668Interchangeable products
Carbolith · DIN 00236683 · $0.0657
PMS-Lithium Carbonate · DIN 02216140 · $0.0657
Shortage status: resolved shortage (ended 2024-12-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242838
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-02-05 — choose a marketed DIN from the same-category list.
Carbolith · DIN 00236683 · 300mg · capsule
General benefitDormant since 2026-07-31 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Carbolith · DIN 00236683
Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01
Health Canada: Dormant since 2026-07-31 · brand CARBOLITH · ATC N05AN01 LITHIUM · form Capsule · route Oral · ingredients LITHIUM CARBONATE 300 MG · company Bausch health, canada inc. · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1327 · Verify on the e-Formulary ↗ (DIN 00236683)
Source record
DIN 00236683: Carbolith
Raw flags: sec3=Y
Item: 281612002; group id 512; item number 1354; lccId None; manufacturer id VAL
Source form: Cap; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $0.1236; ministry $0.0657
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00236683
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1327Interchangeable products
Apo-Lithium Carbonate · DIN 02242838 · $0.0657
PMS-Lithium Carbonate · DIN 02216140 · $0.0657
Shortage status: resolved shortage (ended 2024-09-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00236683
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-07-31 — choose a marketed DIN from the same-category list.
PMS-Lithium Carbonate · DIN 02216140 · 300mg · capsule
General benefitDormant since 2025-08-01 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Lithium Carbonate · DIN 02216140
Manufacturer: Pharmascience Inc.; listing date 1997-04-10
Health Canada: Dormant since 2025-08-01 · brand PMS-LITHIUM CARBONATE - CAP 300MG · ATC N05AN01 LITHIUM · form Capsule · route Oral · ingredients LITHIUM CARBONATE 300 MG · company Pharmascience inc · schedule Prescription
PMS-Lithium Carbonate: Formulary list price $0.0657/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0657 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19933 · Verify on the e-Formulary ↗ (DIN 02216140)
Source record
DIN 02216140: PMS-Lithium Carbonate
Raw flags: sec3=Y
Item: 281612002; group id 512; item number 1354; lccId None; manufacturer id PMS
Source form: Cap; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $0.0657; ministry $0.0657
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02216140
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19933Interchangeable products
Apo-Lithium Carbonate · DIN 02242838 · $0.0657
Carbolith · DIN 00236683 · $0.0657
Shortage status: active shortage (reported not recorded, last updated 2026-08-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02216140
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-08-01 — choose a marketed DIN from the same-category list.
General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Lithium Carbonate · DIN 09857532
Manufacturer: Apotex Inc.; listing date 2003-09-04
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 09857532: Apo-Lithium Carbonate
Raw flags: sec3=Y
Item: 281612014; group id 512; item number 1353; lccId None; manufacturer id APX
Source form: Cap; strength: 150mg
Recorded listing: General benefit
Source prices (unrounded): $0.0667; ministry $0.0667
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09857532
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Lithane · DIN 02013231 · $0.0667
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09857532
Shortage record checked 2026-09-13T08:10:21.292534+00:00
General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Lithium Carbonate · DIN 09857540
Manufacturer: Apotex Inc.; listing date 2003-09-04
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 09857540: Apo-Lithium Carbonate
Raw flags: sec3=Y
Item: 281612016; group id 512; item number 1355; lccId None; manufacturer id APX
Source form: Cap; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $0.0657; ministry $0.0657
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09857540
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Lithane · DIN 00406775 · $0.0657
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09857540
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Duralith · DIN 00590665 · 300mg · extended release tablet
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2010-02-12 — choose a marketed DIN from the same-category list.Discontinued 2010-02-12 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2010-02-12 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2010-02-12 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Duralith · DIN 00590665
Manufacturer: Janssen-Ortho Inc.; listing date 2008-06-27
Health Canada: Cancelled post market since 2010-02-12 · brand DURALITH TAB 300MG · ATC N05AN01 LITHIUM · form Tablet (extended-release) · route Oral · ingredients LITHIUM CARBONATE 300 MG · company Janssen inc · schedule Prescription
Duralith: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6041 · Verify on the e-Formulary ↗ (DIN 00590665)
Source record
DIN 00590665: Duralith
Raw flags: sec3=Y, sec3b=Y
Item: 281612027; group id 512; item number 1356; lccId None; manufacturer id JNO
Source form: ER Tab; strength: 300mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00590665
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6041Interchangeable products
Lithmax · DIN 02266695 · $0.2880
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00590665
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2010-02-12 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:16:12 Other Psychotropics) and how they are covered
Matched class: 28:16:12 Other Psychotropics
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
No displayed product is listed as a general benefit in this extract. Check its listing requirements below.
28:16:12 Other Psychotropics
1 INDICATIONS
LITHANE (lithium carbonate) is indicated for:
the treatment of acute manic episodes in patients with manic-depressive disorders.
Maintenance therapy has been found useful in preventing or diminishing the frequency of subsequent
relapses in bipolar manic-depressive patients (with a strong history of mania).
1.1 Pediatrics
Pediatrics (<18 years of age): Health Canada has not authorized an indication for pediatric use
(see 7.1.3 Pediatrics).
1.2 Geriatrics
Evidence from clinical studies and experience suggests that use in the geriatric population is
associated with differences in safety or effectiveness (see 7.1.4 Geriatrics).
https://pdf.hres.ca/dpd_pm/00067512.PDF
PM date: SEP 21, 2022
Source product: LITHANE; DIN 00406775; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Carbolith · DIN 00461733
Shortage status: discontinued (2025-01-20, reported by BAUSCH HEALTH, CANADA INC.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00461733
Lithane · DIN 02013231
Shortage status: active shortage (reported 2024-05-13, last updated 2026-02-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02013231
Lithane · DIN 00406775
Shortage status: active shortage (reported 2024-07-02, last updated 2026-02-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00406775
PMS-Lithium Carbonate · DIN 02216140
Shortage status: active shortage (reported not recorded, last updated 2026-08-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02216140
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)
Other review policies
For Lithmax, Duralith: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.